Clinical trials: Systolic Heart Failure
Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Trial name
- NCT07795359
- Testing
- Subcutaneous cardiac microcurrent treatment
- Volunteers
- 60 people
- Sponsor
- Berlin Heals GmbH
Heart Failure
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic…
- Trial name
- ARTS-HF (NCT01807221)
- Testing
- Finerenone (BAY94-8862), Inspra (eplerenone)
- Where
- 172 sites in United States, Australia and 23 more
- Volunteers
- 1,066 people
- Sponsor
- Bayer
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORE (NCT07188805)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 133 sites in United States, Argentina and 21 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Congestive Heart Failure
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to…
- Trial name
- NCT02388464
- Testing
- MTP-131
- Where
- Bulgaria
- Volunteers
- 36 people
- Sponsor
- Stealth BioTherapeutics Inc.
Chronic Systolic Heart Failure
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure
A multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of injectable Neucardin on the heart function in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with…
- Trial name
- NCT04468529
- Testing
- Recombinant human Neuregulin for injection
- Where
- 29 sites in China
- Volunteers
- 154 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Chronic Systolic Heart Failure
Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure
A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of recombinant human Neuregulin-1 for injection on cardiac function and reverse ventricular remodeling in male patients…
- Trial name
- NCT05949801
- Testing
- Neucardin
- Where
- 103 sites in China
- Volunteers
- 202 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Congestive Heart Failure, Left Bundle Branch Block
MIRACLE EF Clinical Study
This study is looking at whether the electrical treatment provided by a special type of pacemaker called a Cardiac Resynchronization Therapy (CRT) pacemaker may keep a patient's heart failure from getting worse.
- Conditions
- Congestive Heart Failure, Left Bundle Branch Block, Systolic Heart Failure
- Trial name
- MIRACLE EF (NCT01735916)
- Testing
- CRT-P Implant, CRT-P OFF
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 44 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Cardiac Failure
A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
- Conditions
- Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction
- Trial name
- NCT03357731
- Testing
- HNO Donor, Nitroglycerin (NTG)
- Where
- 18 sites in United States, Japan and 2 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Non-Ischemic Heart Failure, Reduced Ejection Fraction Heart Failure
ASCs in Recently Diagnosed Non-ischemic Heart Failure
The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in…
- Trial name
- ARIISE (NCT06840275)
- Testing
- Allogeneic adipose tissue-derived mesenchymal stem cells, Cryostor CS10
- Where
- Denmark
- Sponsor
- Cell to Cure ApS
Heart Failure
A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of JNJ-54452840 in participants with heart failure and anti-beta1-adrenergic…
- Trial name
- NCT01798745
- Testing
- JNJ-54452840
- Sponsor
- Janssen Research & Development, LLC
Congestive Heart Failure, Left Ventricular (LV) Systolic Dysfunction
A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System
Treatment of ischemic heart failure.
- Trial name
- PARACHUTE IV (NCT01614652)
- Testing
- CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
- Where
- 68 sites in United States, Canada
- Volunteers
- 331 people
- Sponsor
- CardioKinetix, Inc
Heart Failure
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study.
- Trial name
- NCT01096043
- Testing
- Strata 1 CXL-1020, Strata 2 CXL-1020, Strata 3 CXL-1020
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
Crestor Versus Placebo in Subjects With Heart Failure
The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal…
- Trial name
- NCT00206310
- Testing
- CRESTOR
- Where
- 375 sites in Belgium, Bulgaria and 19 more
- Volunteers
- 5,013 people
- Sponsor
- AstraZeneca